Skip to main content

Table 6 Best overall response as determined by investigator (response-evaluable population)

From: Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study

 

Hepatic function

 

Normal

(n = 10)

Mild impairment

(n = 15)

Moderate impairment

(n = 9)

Severe impairment

(n = 0)

Total

(n = 34)

Best overall response—n (%)

 Complete response

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Partial response

1 (10.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (2.9)

 Stable disease

4 (40.0)

1 (6.7)

2 (22.2)

0 (0.0)

7 (20.6)

 Progressive disease

5 (50.0)

12 (80.0)

4 (44.4)

0 (0.0)

21 (61.8)

 Not evaluable

0 (0.0)

2 (13.3)

3 (33.3)

0 (0.0)

5 (14.7)

  1. Disease response was determined for solid tumor malignancies using Response Evaluation Criteria in Solid Tumors (RECIST)
  2. Disease response was determined for myeloma using the International Myeloma Working Group Uniform Response Criteria (IMWG-URC), except for minimal response which was based on the European Group for Blood and Marrow Transplantation (EBMT) criteria